Epilepsy – Special Topics – Epilepsy Special Topics New Treatments In Epilepsy US
More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to AED treatment. Opportunity in this arena has spurred the development of a range of new AEDs targeting drug-resistant epilepsy, particularly highly refractory orphan pediatric subpopulations such as Lennox-Gastaut syndrome, Dravet syndrome, and acute repetitive seizures. In the past two years, six AEDs have been FDA-approved for refractory patients, and one more is on the near-term horizon. Understanding how prescribers perceive and plan to incorporate new brands in epilepsy is critical for developers facing a complicated, highly generic, and increasingly competitive market.
How do neurologists perceive the clinical profiles of recently launched and emerging brands?
How do neurologists currently prescribe or plan to prescribe new brands? How will they be incorporated into the treatment algorithm?
What are the top reasons why some neurologists do not prescribe or would refrain from prescribing recently launched or emerging brands?
How will the availability of new brands impact current prescribing for the broad epilepsy population, as well as for niche epilepsy subpopulations?
Epilepsy - Special Topics - Epilepsy Special Topics New Treatments In Epilepsy US
Special Topics - New Treatments in Epilepsy - US - October 2020
Niyati Khetarpal, Ph.D.
Niyati Khetarpal, M.Sc., M.B.A., Ph.D., is a senior analyst on the CNS/Ophthalmology Disorders team at Clarivate. In this role, she conducts primary and secondary research to analyze pharmaceutical markets, with a focus on neurology indications, including epilepsy and MS. She also has specific expertise in patent/IP research. Dr. Khetarpal obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology in New Delhi, where she conducted research on Dengue virus vaccines. In 2014, she received a Fulbright-Nehru doctoral scholarship for her research on Dengue and West Nile virus envelope proteins.